TPI [TIANYIN PHARMACEUTICAL] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x For the quarterly period ended March 31, 2014 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +86 028 8551 6696 (Address, including] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2014 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2014 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman EX-32.1 4 f10q0314ex32i_tianyin.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Director EX-32.2 5 f10q0314ex32ii_tianyin.htm CERTIFICATION]

By | 2016-03-19T15:35:53+00:00 May 15th, 2014|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 10-Q: FORM 10-Q (Mark One) x For the quarterly

[FORM 10-Q (Mark One) x For the quarterly period ended March 31, 2014 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +86 028 8551 6696 (Address, including] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2014 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2014 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman EX-32.1 4 f10q0314ex32i_tianyin.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Director EX-32.2 5 f10q0314ex32ii_tianyin.htm CERTIFICATION]

By | 2016-03-19T15:37:37+00:00 May 15th, 2014|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q: (Original Filing)

[] [CONSULTING SERVICES AGREEMENT Agreement Company Consultant This CONSULTING SERVICES AGREEMENT (this “ RECITALS: WHEREAS, Board Representative WHEREAS Prior Consulting Agreement WHEREAS WHEREAS NOW, THEREFORE, in consideration of the foregoing recitals and the mutual agreements herein contained and for other good and valuable consideration, the Parties hereto agree as follows: 1. Continuing Services as the Representative Services Prior to This Agreement] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. May 15, 2014 Weibing Lu Chief Executive Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. May 15, 2014 Bing Mei Chief Financial Officer]

By | 2016-03-27T16:03:04+00:00 May 15th, 2014|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q:

[] [CONSULTING SERVICES AGREEMENT Agreement Company Consultant This CONSULTING SERVICES AGREEMENT (this “ RECITALS: WHEREAS, Board Representative WHEREAS Prior Consulting Agreement WHEREAS WHEREAS NOW, THEREFORE, in consideration of the foregoing recitals and the mutual agreements herein contained and for other good and valuable consideration, the Parties hereto agree as follows: 1. Continuing Services as the Representative Services Prior to This Agreement] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. May 15, 2014 Weibing Lu Chief Executive Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. May 15, 2014 Bing Mei Chief Financial Officer]

By | 2016-03-27T16:04:00+00:00 May 15th, 2014|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K/A: (Original Filing)

[CURRENT REPORT FOR ISSUERS SUBJECT TO THE Amendment No. 1 to FORM 8-K CURRENT REPORT May 9, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041]

By | 2016-03-19T15:38:51+00:00 May 14th, 2014|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K/A: CURRENT REPORT FOR ISSUERS SUBJECT TO THE Amendment

[CURRENT REPORT FOR ISSUERS SUBJECT TO THE Amendment No. 1 to FORM 8-K CURRENT REPORT May 9, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041]

By | 2016-03-19T15:40:47+00:00 May 14th, 2014|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)

[CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT April 30, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8551-6696 o o o]

By | 2016-03-19T15:42:17+00:00 May 6th, 2014|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K: CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM

[CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT April 30, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8551-6696 o o o]

By | 2016-03-19T15:43:20+00:00 May 6th, 2014|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Files 2013 Annual Report on Form 20-F The Company will provide a hard copy of its complete audited financial statements to its shareholders upon request, free of charge. Requests for a hard copy of the 2013 Annual Report can be made through the Contact IR page in the Investor Relations section of the Company's website by submitting complete mailing] [Sinovac Receives Notification of China Government Grant for EV71 Vaccine Project -- RMB 60 Million Free Grant for Construction of Dedicated Production Facility SVA BEIJING, April 24, 2014 -- Sinovac Biotech Ltd. (NASDAQ: Enterovirus 71 (EV71) vaccine against hand foot and mouth disease (HFMD). Given the severity of HFMD epidemic levels in China and the government’s focus on developing the] []

By | 2016-03-16T07:17:44+00:00 April 28th, 2014|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Files 2013 Annual Report on Form 20-F

[Sinovac Files 2013 Annual Report on Form 20-F The Company will provide a hard copy of its complete audited financial statements to its shareholders upon request, free of charge. Requests for a hard copy of the 2013 Annual Report can be made through the Contact IR page in the Investor Relations section of the Company's website by submitting complete mailing] [Sinovac Receives Notification of China Government Grant for EV71 Vaccine Project -- RMB 60 Million Free Grant for Construction of Dedicated Production Facility SVA BEIJING, April 24, 2014 -- Sinovac Biotech Ltd. (NASDAQ: Enterovirus 71 (EV71) vaccine against hand foot and mouth disease (HFMD). Given the severity of HFMD epidemic levels in China and the government’s focus on developing the] []

By | 2016-03-16T07:18:40+00:00 April 28th, 2014|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar